Landscape of biallelic DNMT3A mutant myeloid neoplasms.

Humans DNA Methyltransferase 3A DNA (Cytosine-5-)-Methyltransferases / genetics Male Female Mutation Retrospective Studies Middle Aged Leukemia, Myeloid, Acute / genetics Adult Aged Alleles Young Adult Aged, 80 and over Adolescent Myeloproliferative Disorders / genetics Gene Frequency
DNMT3A mutation Acute myeloid leukemia Myelodysplastic syndrome Myeloproliferative neoplasms

Journal

Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937

Informations de publication

Date de publication:
27 Sep 2024
Historique:
received: 28 06 2024
accepted: 15 09 2024
medline: 28 9 2024
pubmed: 28 9 2024
entrez: 28 9 2024
Statut: epublish

Résumé

DNA methyltransferase 3 A mutations (DNMT3A

Identifiants

DOI: 10.1186/s13045-024-01607-9 PMID: 39334207
pubmed: 39334207
doi: 10.1186/s13045-024-01607-9
pii: 10.1186/s13045-024-01607-9
doi:

Substances chimiques

DNA Methyltransferase 3A EC 2.1.1.37
DNMT3A protein, human 0
DNA (Cytosine-5-)-Methyltransferases EC 2.1.1.37

Types de publication

Letter Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

87

Subventions

Organisme : Instituto de Salud Carlos III
ID : JR22/00041
Organisme : NHLBI NIH HHS
ID : R35HL135795
Pays : United States

Informations de copyright

© 2024. The Author(s).

Références

Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen A, et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood. 2013;121(23):4769–77.
doi: 10.1182/blood-2012-10-461624 pubmed: 23632886
Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424–33.
doi: 10.1056/NEJMoa1005143 pubmed: 21067377 pmcid: 3201818
Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506(7488):328–33.
doi: 10.1038/nature13038 pubmed: 24522528 pmcid: 4991939
Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011;25(7):1153–8.
doi: 10.1038/leu.2011.44 pubmed: 21415852 pmcid: 3202965
Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488–98.
doi: 10.1056/NEJMoa1408617 pubmed: 25426837 pmcid: 4306669
Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477–87.
doi: 10.1056/NEJMoa1409405 pubmed: 25426838 pmcid: 4290021
Yang L, Rau R, Goodell MA. DNMT3A in haematological malignancies. Nat Rev Cancer. 2015;15(3):152–65.
doi: 10.1038/nrc3895 pubmed: 25693834 pmcid: 5814392
Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2011;44(1):23–31.
doi: 10.1038/ng.1009 pubmed: 22138693 pmcid: 3637952
Zhang X, Wang X, Wang XQD, Su J, Putluri N, Zhou T, et al. Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis. Blood. 2020;135(11):845–56.
doi: 10.1182/blood.2019003330 pubmed: 31932841 pmcid: 7068035
Narayanan D, Pozdnyakova O, Hasserjian RP, Patel SS, Weinberg OK. Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML. Blood Adv. 2021;5(11):2539–49.
doi: 10.1182/bloodadvances.2021004250 pubmed: 34100902 pmcid: 8238486

Auteurs

Naomi Kawashima (N)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, 9620 Carnegie Ave, Building NE6-312, Cleveland, OH, 44106, USA.

Yasuo Kubota (Y)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, 9620 Carnegie Ave, Building NE6-312, Cleveland, OH, 44106, USA.

Carlos Bravo-Perez (C)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, 9620 Carnegie Ave, Building NE6-312, Cleveland, OH, 44106, USA.
Department of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, University of Murcia, IMIB-Pascual Parrilla, CIBERER - Instituto de Salud Carlos III, Murcia, Spain.

Luca Guarnera (L)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, 9620 Carnegie Ave, Building NE6-312, Cleveland, OH, 44106, USA.
Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

Nakisha D Williams (ND)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, 9620 Carnegie Ave, Building NE6-312, Cleveland, OH, 44106, USA.

Arda Durmaz (A)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, 9620 Carnegie Ave, Building NE6-312, Cleveland, OH, 44106, USA.

Michaela Witt (M)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, 9620 Carnegie Ave, Building NE6-312, Cleveland, OH, 44106, USA.

Arooj Ahmed (A)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, 9620 Carnegie Ave, Building NE6-312, Cleveland, OH, 44106, USA.

Carmelo Gurnari (C)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, 9620 Carnegie Ave, Building NE6-312, Cleveland, OH, 44106, USA.
Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

Jaroslaw P Maciejewski (JP)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, 9620 Carnegie Ave, Building NE6-312, Cleveland, OH, 44106, USA.

Valeria Visconte (V)

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, 9620 Carnegie Ave, Building NE6-312, Cleveland, OH, 44106, USA. visconv@ccf.org.
ORCID: 0000-0002-2993-1509

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Landscape of biallelic DNMT3A mutant myeloid neoplasms.
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › One-carbon group transferases › Methyltransferases › DNA modification methylases › DNA-Cytosine Methylases › DNA (cytosine-5-)-methyltransferase › DNA methyltransferase 3A › Landscape of biallelic DNMT3A mutant myeloid neoplasms.
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › One-carbon group transferases › Methyltransferases › DNA modification methylases › DNA-Cytosine Methylases › DNA (cytosine-5-)-methyltransferase › Landscape of biallelic DNMT3A mutant myeloid neoplasms.
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Landscape of biallelic DNMT3A mutant myeloid neoplasms.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Landscape of biallelic DNMT3A mutant myeloid neoplasms.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Landscape of biallelic DNMT3A mutant myeloid neoplasms.
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › Landscape of biallelic DNMT3A mutant myeloid neoplasms.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Landscape of biallelic DNMT3A mutant myeloid neoplasms.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Landscape of biallelic DNMT3A mutant myeloid neoplasms.
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Allèles › Landscape of biallelic DNMT3A mutant myeloid neoplasms.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › Landscape of biallelic DNMT3A mutant myeloid neoplasms.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Landscape of biallelic DNMT3A mutant myeloid neoplasms.
questionsmedicales.fr › Personnes › Tranches d'âge › Adolescent › Landscape of biallelic DNMT3A mutant myeloid neoplasms.
questionsmedicales.fr › Hémopathies et maladies lymphatiques › Hémopathies › Maladies de la moelle osseuse › Syndromes myéloprolifératifs › Landscape of biallelic DNMT3A mutant myeloid neoplasms.
questionsmedicales.fr › Phénomènes génétiques › Fréquence d'allèle › Landscape of biallelic DNMT3A mutant myeloid neoplasms.